
-
Lyra Therapeutics NasdaqCM:LYRA Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Location: 480 Arsenal Way, Watertown, MA, 02472, United States | Website: https://lyratherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
8.261M
Cash
31.74M
Avg Qtr Burn
-14.1M
Short % of Float
15.59%
Insider Ownership
0.83%
Institutional Own.
48.65%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LYR-210 (anti-inflammatory implantable drug matrix) Details Rhinosinusitis, Chronic rhinosinusitis, Neurological disorder Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
LYR-220 (Long-acting Mometasone Furoate) Details Chronic rhinosinusitis | Phase 2 Update |